Skip to main content
SRTAStrata Critical Medical, Inc.Sell6.5·$4.76
SellModerate Confidence
Investment thesis

Strata Critical Medical shows standout revenue growth and a favorable engine-calculated risk/reward setup, but earnings quality red flags, a volatile earnings track record, and ongoing insider selling temper the bullish growth narrative.

Thesis pillars

  • Strong Revenue Growth Industry Leader→Stable
  • Earnings Quality Red Flag→Stable
  • Favorable Risk Reward Asymmetry→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 3, 2026

Full reasoning →

Open full analysis

Strata Critical Medical, Inc. (SRTA) Stock Analysis

Inst Constrain edge

SellGrowthQualityModerate Confidence

Healthcare · Medical Care Facilities

Earnings in 4 days (2026-11-03). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $4.76: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.

Strata Critical Medical (formerly Blade Air Mobility) is a time-critical logistics and clinical services provider to the U.S. transplant industry, operating one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement... Read more

$4.76+70.8% A.UpsideScore 6.5/10#1 of 35 Medical Care Facilities
QualityF-score4 / 9FCF yield-4.77%
Stop $4.43Analyst target $8.13(−15% haircut)A.R:R 6.1:1
Analyst consensus$9.56+100.9%4 analysts
$8.13Analyst target
$4.76price
$9.56mean
$13

Sell if holding. Engine safety override at $4.76: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.5/10, moderate confidence.

Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 4d<=7d. Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-10-29
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Nov 3, 20264d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.0 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)—
Mkt Cap$421M
EV/EBITDA55.7
Profit Mgn15.7%
ROE-9.2%
Rev Growth60.7%
Beta2.43
DividendNone
Rating analysts10

Quality Signals

Piotroski F4/9MoatNarrow

Options Flow

P/C0.04bullish
IV83%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomertransplant centers and OPOs
    10-K Item 1A: 'The transplant ecosystem in the United States is relatively concentrated among a limited number of transplant centers and OPOs'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·2 ceiling hits

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Fcf Quality
0.0
Gross Margin
0.3
Piotroski F
4.4
Moat
5.8
Net Margin
7.9
Current Ratio
8.9
Strong margins: 16%Earnings quality RED FLAG: -50% FCF/NI

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
5.0
Earnings Timing
5.0
News Activity
6.0
Earnings concerns: 1B/3MEarnings in 4 days

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
2.9
Support Resistance
4.0
52w Position
4.6
GatesEARNINGS PROXIMITY 4d<=7dMomentum 5.1<5.5 (soft — BUY_NOW allowed but watch)Momentum 5.1>=4.5A.R:R 6.1 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
64 · Neutral
↑ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $4.21Resistance $5.12

Price Targets

$4
$8
A.Upside+70.8%
A.R:R6.1:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (3.0 < 4.0)
! EARNINGS_PROXIMITY:4d<=7d

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-11-03 (4d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SRTA stock a buy right now?

Sell if holding. Engine safety override at $4.76: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.5/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $4.43. Score 6.5/10, moderate confidence.

What is the SRTA stock price target?

Analyst target: $8.13 (+70.8% upside). Prior stop was $4.43. Stop-loss: $4.43.

What are the risks of investing in SRTA?

Quality below floor (3.0 < 4.0).

Is SRTA overvalued or undervalued?

Strata Critical Medical, Inc. trades at a P/E of N/A (forward N/A). TrendMatrix value score: 9.1/10. Verdict: Sell.

What do analysts say about SRTA?

10 analysts cover SRTA with a consensus score of 4.2/5. Average price target: $10.

What does Strata Critical Medical, Inc. do?Strata Critical Medical (formerly Blade Air Mobility) is a time-critical logistics and clinical services provider to...

Strata Critical Medical (formerly Blade Air Mobility) is a time-critical logistics and clinical services provider to the U.S. transplant industry, operating one of the nation's largest air transport and surgical services networks for transplant hospitals and organ procurement organizations under the Trinity (Logistics) and Keystone (Clinical) brands. After divesting its legacy Passenger air mobility business to Joby Aero in August 2025 and acquiring Keystone in September 2025, the company now serves Medical Customers exclusively, making it more concentrated and less diversified than before.

Related stocks: ASTH (Astrana Health Inc.) · AVAH (Aveanna Healthcare Holdings Inc) · STLN (Starling Oncology, Inc.) · ADUS (Addus HomeCare Corporation) · NUTX (Nutex Health Inc.)
Home › Stocks › SRTA

Latest news

Latest News

Fiscal.ai4d ago
Fiscal.ai5d agoEarnings
Benzinga13d ago
Benzinga13d agoEarnings
Benzinga14d ago
Benzinga14d ago
Benzinga14d ago
Benzinga31d agoEarnings
Benzinga86d agoEarnings
Benzinga86d agoEarnings
Benzinga86d agoEarnings